search
Back to results

Safety and Efficacy of HydroLenz for Vitrectomy-Induced Lens Opacities

Primary Purpose

Pars Plana Vitrectomy

Status
Not yet recruiting
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
HydroLenz Injection
No HydroLenz Injection
Sponsored by
PromiSight, LLC
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Pars Plana Vitrectomy

Eligibility Criteria

65 Years - undefined (Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Male or female of any race.
  2. 65 years of age or older.
  3. Study eye is phakic and scheduled for pars plana vitrectomy (23, 25, or 27 gauge) for epiretinal membrane or vitreomacular traction surgery.
  4. Willingness and ability to comply with schedule for follow-up visits.
  5. Subject understands the study requirements and the treatment procedures and provides signed, written informed consent obtained in accordance with the institutional review board (or ethics committee) requirements for this first-in-man early feasibility study.

Exclusion Criteria:

  1. Aphakic or pseudophakic lens status in either or both eyes.
  2. History of previous cataract surgery in either eye.
  3. Evidence of congenital cataract.
  4. Study eye with corneal opacity of one of the following LOCS III grades or condition that would confound the LOCS III grading results:

    1. Inability to grade opacities in the study eye with LOCS III at the baseline exam;
    2. Inability to dilate pupil to at least 6.0 mm;
    3. LOCS III grade ≥ 2 for nuclear opalescence, cortical lens opacities, or posterior subcapsular lens opacities in the study eye at baseline.
  5. Diabetic retinopathy or macular edema in the study eye.
  6. Retinal vascular disease or retinopathy in the study eye.
  7. History of previous intravitreal injections in the study eye.
  8. History of previous subconjunctival injections in the study eye.
  9. History of previous radiation in the study eye.
  10. History of systemic, periocular, inhaled, or chronic topical corticosteroids.
  11. Previous laser prophylaxis for retinal tear/hole/lattice degeneration in the study eye.
  12. Previous pneumatic retinopexy or retinal detachment repair in the study eye.
  13. Previous vitrectomy in the study eye.
  14. Previous laser treatment anywhere in the study eye (trabecular meshwork, iris, retina, macula).
  15. Use of silicone oil, air or gas tamponade during the vitrectomy in the study eye prior to injection of the HydroLenz.
  16. Use of binocular indirect ophthalmoscopy laser during the procedure (endolaser is permitted).
  17. History of any previous ocular surgery in the study eye.
  18. Any ocular trauma resulting in lens opacity or subluxation of the lens in the study eye.
  19. Iatrogenic lens trauma during surgery prior to injection of the HydroLenz.
  20. Surgical plan for the vitrectomy includes planned glaucoma filtering or tube-shunt procedure or any procedure affecting the lens.
  21. Female patients who are pregnant or lactating or plan to become pregnant during the course of the study.
  22. A known sensitivity to study medications for which no alternative medication can be - prescribed.
  23. Presence or history of any other condition or finding that, in the investigator's opinion, makes the patient unsuitable as a candidate for the HydroLenz treatment or study participation or may confound the outcome of the study.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm Type

    Experimental

    Experimental

    Placebo Comparator

    Arm Label

    Low dose HydroLenz treatment

    High dose HydroLenz treatment

    Control, i.e., no HydroLenz treatment

    Arm Description

    Outcomes

    Primary Outcome Measures

    Evaluation of Changes in Lens Opacities
    The Lens Opacity Classification System, Version III (LOCS III) and the rate of lens related (cataract) surgery will be used to evaluate the lens opacities.
    Evaluation of Changes in Lens Opacities
    The Lens Opacity Classification System, Version III (LOCS III) and the rate of lens related (cataract) surgery will be used to evaluate the lens opacities.
    Changes in BSCVA
    Number of eyes losing more than 2 lines of BSCVA
    Changes in BSCVA
    Number of eyes losing more than 2 lines of BSCVA

    Secondary Outcome Measures

    Full Information

    First Posted
    October 18, 2022
    Last Updated
    May 5, 2023
    Sponsor
    PromiSight, LLC
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05592912
    Brief Title
    Safety and Efficacy of HydroLenz for Vitrectomy-Induced Lens Opacities
    Official Title
    Safety and Preliminary Efficacy of Two Dose Levels of HydroLenz as a Protectant for Vitrectomy-Induced Lens Opacities in Subjects Undergoing Vitrectomy
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    May 2023
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    January 1, 2024 (Anticipated)
    Primary Completion Date
    January 1, 2025 (Anticipated)
    Study Completion Date
    January 1, 2025 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    PromiSight, LLC

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    Yes
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    The primary objective of this study is to provide safety data for two different dosages of HydroLenz. Secondary objectives are to provide preliminary data to determine whether HydroLenz has the same effect in humans as it does in the porcine model; to confirm the reliability of methods for evaluating lens opacity; and, to acquire information that can be used to design the pivotal study.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Pars Plana Vitrectomy

    7. Study Design

    Primary Purpose
    Prevention
    Study Phase
    Phase 1
    Interventional Study Model
    Sequential Assignment
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    36 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Low dose HydroLenz treatment
    Arm Type
    Experimental
    Arm Title
    High dose HydroLenz treatment
    Arm Type
    Experimental
    Arm Title
    Control, i.e., no HydroLenz treatment
    Arm Type
    Placebo Comparator
    Intervention Type
    Drug
    Intervention Name(s)
    HydroLenz Injection
    Intervention Description
    The HydroLenz injection will be administered at the conclusion of the vitrectomy procedure on the operative day
    Intervention Type
    Other
    Intervention Name(s)
    No HydroLenz Injection
    Intervention Description
    No HydroLenz injection will be administered at the conclusion of the vitrectomy procedure on the operative day.
    Primary Outcome Measure Information:
    Title
    Evaluation of Changes in Lens Opacities
    Description
    The Lens Opacity Classification System, Version III (LOCS III) and the rate of lens related (cataract) surgery will be used to evaluate the lens opacities.
    Time Frame
    Baseline and 6 Months
    Title
    Evaluation of Changes in Lens Opacities
    Description
    The Lens Opacity Classification System, Version III (LOCS III) and the rate of lens related (cataract) surgery will be used to evaluate the lens opacities.
    Time Frame
    Baseline and 12 Months
    Title
    Changes in BSCVA
    Description
    Number of eyes losing more than 2 lines of BSCVA
    Time Frame
    Baseline and 6 Months
    Title
    Changes in BSCVA
    Description
    Number of eyes losing more than 2 lines of BSCVA
    Time Frame
    Baseline and 12 Months

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    65 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Male or female of any race. 65 years of age or older. Study eye is phakic and scheduled for pars plana vitrectomy (23, 25, or 27 gauge) for epiretinal membrane or vitreomacular traction surgery. Willingness and ability to comply with schedule for follow-up visits. Subject understands the study requirements and the treatment procedures and provides signed, written informed consent obtained in accordance with the institutional review board (or ethics committee) requirements for this first-in-man early feasibility study. Exclusion Criteria: Aphakic or pseudophakic lens status in either or both eyes. History of previous cataract surgery in either eye. Evidence of congenital cataract. Study eye with corneal opacity of one of the following LOCS III grades or condition that would confound the LOCS III grading results: Inability to grade opacities in the study eye with LOCS III at the baseline exam; Inability to dilate pupil to at least 6.0 mm; LOCS III grade ≥ 2 for nuclear opalescence, cortical lens opacities, or posterior subcapsular lens opacities in the study eye at baseline. Diabetic retinopathy or macular edema in the study eye. Retinal vascular disease or retinopathy in the study eye. History of previous intravitreal injections in the study eye. History of previous subconjunctival injections in the study eye. History of previous radiation in the study eye. History of systemic, periocular, inhaled, or chronic topical corticosteroids. Previous laser prophylaxis for retinal tear/hole/lattice degeneration in the study eye. Previous pneumatic retinopexy or retinal detachment repair in the study eye. Previous vitrectomy in the study eye. Previous laser treatment anywhere in the study eye (trabecular meshwork, iris, retina, macula). Use of silicone oil, air or gas tamponade during the vitrectomy in the study eye prior to injection of the HydroLenz. Use of binocular indirect ophthalmoscopy laser during the procedure (endolaser is permitted). History of any previous ocular surgery in the study eye. Any ocular trauma resulting in lens opacity or subluxation of the lens in the study eye. Iatrogenic lens trauma during surgery prior to injection of the HydroLenz. Surgical plan for the vitrectomy includes planned glaucoma filtering or tube-shunt procedure or any procedure affecting the lens. Female patients who are pregnant or lactating or plan to become pregnant during the course of the study. A known sensitivity to study medications for which no alternative medication can be - prescribed. Presence or history of any other condition or finding that, in the investigator's opinion, makes the patient unsuitable as a candidate for the HydroLenz treatment or study participation or may confound the outcome of the study.
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Jodi S Pitcher
    Phone
    513-961-8200
    Email
    jlpitcher@crc-regulatory.com

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    Safety and Efficacy of HydroLenz for Vitrectomy-Induced Lens Opacities

    We'll reach out to this number within 24 hrs